Dr Chakor Vora - Mechanism Of Resistance To Osimeritinib In EGFR Mutated Lung Cancer

Dr Chakor Vora is speaking about what should be the follow-up protocol for a lung cancer patientПодробнее

Dr Chakor VoraПодробнее

Mechanisms of Resistance to Upfront EGFR-Targeted TherapyПодробнее

Mechanisms of osimertinib resistance in AURA 3Подробнее

Dr. Goldberg on Resistance to Osimertinib for NSCLCПодробнее

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLCПодробнее

Resistance to Osimertinib in EGFR-Mutated NSCLCПодробнее

Dr Chakor Vora | phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E MutantПодробнее

Resistance to Osimertinib in EGFR-Mutated NSCLCПодробнее

Resistance Mechanisms in EGFR+ NSCLCПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

NSCLC: EGFR Inhibition and Resistance MechanismsПодробнее

Acquired Resistance to Osimertinib in T790M-Positive NSCLCПодробнее

Resistance Mechanisms in EGFR-Positive NSCLCПодробнее

Acquired Resistance to Osimertinib in EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum - EnglishПодробнее

Dr. Padda on Overcoming Resistance to Osimertinib in EGFR+ NSCLCПодробнее

Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLCПодробнее

Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With OsimertinibПодробнее

MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLCПодробнее